Wird geladen...
EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression
BACKGROUND: Increasing evidence suggests the involvement of enhancer of zeste homologue 2 (EZH2) in chemoresistance of cancer treatment. Nevertheless, its function and molecular mechanisms in gastric cancer (GC) chemoresistance are still not well elucidated. MATERIALS AND METHODS: In the present stu...
Gespeichert in:
| Veröffentlicht in: | Onco Targets Ther |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6225849/ https://ncbi.nlm.nih.gov/pubmed/30464532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S180131 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|